FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Reuters) -The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly's COVID-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease.
The cocktail, bamlanivimab and etesevimab, was authorized in February for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.
However, the FDA said on Thursday the cocktail is not a substitute for vaccination against COVID-19. (https://bit.ly/2XqtHln)
The FDA said that bamlanivimab and etesevimab, which are administered together, could be also used as post-exposure prevention for patients who are not fully vaccinated or who are not expected to mount an adequate immune response to complete vaccination or have been exposed to an individual infected with the virus.
The revision comes a day after the U.S. government bought 388,000 additional doses of Lilly's COVID-19 antibody therapy.
(Reporting by Dania Nadeem in Bengaluru; Editing by Shailesh Kuber)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biopharma stocks: Mizuho Expects Eli Lilly (LLY) to Beat, Pfizer (PFE) to Miss and AbbVie (ABBV) to Report Mixed Q3 Earnings
- Cabaletta Bio (CABA) Reports Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy
- Merck (MRK), Eisai Receive Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Two Different Types of Cancer
Create E-mail Alert Related CategoriesFDA, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!